Here are the key facts of this story, as agreed upon by Reuters, Bloomberg, CNBC, and FOX News. On Mon., Pfizer announced that it will acquire the blood disorder drugmaker Global Blood Therapeutics for $5.4B, at a cost of $68.50 per share. Ahead of the announcement, Global Blood — which…